NCT03368677Active, not recruiting
Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression
Targeting SPMS: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression. A [11C]PK11195 Brain PET Study
Source: ClinicalTrials.gov · Last updated 13 Apr 2025
Brief summary (registry, in English)
To evaluate the effect of teriflunomide treatment on microglial activation in late stage multiple sclerosis.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 26 (actual)
- First submitted
- 2 Oct 2017
- Start date
- 1 Dec 2017
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Turku University Hospital
- Diseases
- Multiple sclerosis
- NCT number
- NCT03368677
What you commit to
- Study type: Observational
- Participants enrolled: 26
- From 1 Dec 2017 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Steroid treatment 4 weeks prior to the scan
- Pregnant women, or women of childbearing potential who are not using reliable contraception during treatment with teriflunomide and thereafter as long as its plasma levels are above 0.02 mg/l.
Other illness
- Patients suffering from another brain disease of in addition to multiple sclerosis
- Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
- Severe hepatic impairment
Other
- Significant pathology in the MRI scan other than MS-related lesions
- Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
Who the study is looking for
- Signing the consent form
- Having used teriflunomide treatment for at least 6 months
- 40-55 years of age at the time of signing the research consent form
- MS diagnosis in accordance with either the Poser or McDonald criteria
- EDSS 2-6.5
- Clear lesion load in brain MRI (\> 9 T2 lesion)
Age in the registry: 40 years to 55 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Turku PET Centre Coordinator of this site? Confirm its status | Turku | Finland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.